期刊文献+

人血清生长分化因子15与冠心病患者慢性心力衰竭的相关性研究 被引量:7

Association of the growth differentiation factor-15 with chronic heart failure in coronary heart disease patients
下载PDF
导出
摘要 目的 探讨生长分化因子15(GDF-15)与冠心病患者慢性心力衰竭的关系及诊断价值.方法 选择复旦大学附属华山医院心内科269例行冠状动脉造影(CAG)检查的患者,根据CAG、心电图及心肌酶学检查结果分为3组:其中冠心病心肌梗死患者98例(MI组),本组再根据纽约心脏病协会(NYHA)心功能分级Ⅰ~Ⅳ级分为4个亚组;未经历心肌梗死的冠心病患者84例(CAD组);CAG正常患者87例(对照组).采用酶联免疫吸附法测定患者GDF-15浓度.分析GDF-15与NYHA分级和血清N末端脑钠肽原(NT-proBNP)的关系.结果 MI组平均及其各不同心功能分级亚组[纽约心脏病协会(NYHA)Ⅰ级、Ⅱ级、Ⅲ级、Ⅳ级]、CAD组血清GDF-15浓度明显高于对照组,差异有统计学意义[1 622(888,1 995),983 (808,1 501)、1 614(810,1 825)、1 940(1 837,2 063)、3 905(3 690,4 019),945(856,1 000) ng/L比798 (728,873) ng/L] (P <0.05).MI组平均及其各不同心功能分级亚组(NYHA Ⅰ级、Ⅱ级、Ⅲ级、Ⅳ级)血清NT-proBNP浓度明显高于对照组,差异有统计学意义[564(158,857),233(105,552)、278(133,716)、790(636,1 490)、4 665(3 712,5 442) ng/L比121(108,134)ng/L] (P <0.05).相关性分析显示GDF-15水平与血清NT-proBNP水平呈显著正相关(r=0.861,P<0.01),与血清LVEF呈显著负相关(r=-0.936,P<0.01).GDF-15与NT-proBNP对慢性心力衰竭的受试者工作特征曲线结果显示其下面积分别为0.804、0.795(P <0.01).GDF-15的最佳临界值为1 086.38 ng/L时,对慢性心力衰竭诊断的敏感性为72.4%,特异性为93.6%.结论 GDF-15是一个新的冠心病患者慢性心力衰竭预后诊断标志物,能够对心力衰竭的严重程度进行客观评价. Objective To explore the diagnostic value of the growth differentiation factor-15 (GDF-15) level in plasma and its relationship with chronic heart failure in coronary heart disease patients.Methods Totally 98 coronary heart disease patients with chronic heart failure(myocardial infarction group) or without chronic heart failure(coronary artery disease group) were enrolled in the study.Plasma GDF-15 level was determined with enzyme linked immunoadsorbent assay method and compared with 87 normal coronary artery disease patients (control group).Results GDF-15 average level in myocardial infarction group,its various subgroups of cardiac function classification (New York Heart Association Ⅰ,Ⅱ,Ⅲ,Ⅳ) and coronary artery disease group were significant higher than those in control group[1 622(888,1 995),983 (808,1 501),1 614(810,1 825),1 940(1 837,2 063),3 905 (3 690,4 019),945 (856,1 000) ng/L vs 798 (728,873) ng/L] (P 〈 0.05).N-terminal pro-brain natriuretic peptide (NT-proBNP) average level in myocardial infarction group and its various subgroups of cardiac function classification (New York Heart Association Ⅰ,Ⅱ,Ⅲ,Ⅳ) were significant higher than control group [564 (158,857),233 (105,552),278 (133,716),790 (636,1 490),4 665 (3 712,5 442) ng/L vs 121 (108,134) ng/L] (P 〈0.05).Mter adjustment,plasma GDF-15 level was found to be related to the proved clinical maker NT-proBNP (r =0.861,P 〈 0.01),it was negative correlated with left ventricular ejection fraction(r =-0.936,P 〈 0.01).The receiver operating characteristic curve of the GDF-15 level and NT-proBNP level was constructed and the area under concentration for continuous untransformed GDF-15 was 0.804,0.795 (P 〈 0.01).Best critical value of GDF-15 was 1 086.38 ng/L,the diagnosis of chronic heart failure sensitivity was 72.4%,specificity was 93.6%.Conclusion GDF-15 can be used as a new prognostic biomarker of chronic heart failure.
作者 朱志栋 孙韬
出处 《中国医药》 2014年第2期149-153,共5页 China Medicine
关键词 冠心病 慢性心力衰竭 生长分化因子15 N末端脑钠肽原 相关性分析 受试者工作特征曲线 Growth differentiation factor-15 Coronary heart disease Chronic heart failure N-terminal pro-brain natriuretic peptide Association analysis Receiver operating characteristic curve
  • 相关文献

参考文献15

  • 1Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-I, a novel macrophage inhibito:: cytokine, is a divergent member of the TGF- beta superfamily[ J]. Proc Natl Acad Sci U S A, 1997,94(21 ) : 11514-11519.
  • 2Tan M, Wang Y, Guan K, et al. PTGF-beta, a type beta transfor- ming growth faetor (TGF-beta) supertamily member, is a p53 tar- get gene that inhibits tumor cell growth via TGF-beta signaling pathway: J]. Proe Natl Aead Sei U S A, 2000,97 ( 1 ) : 109-114.
  • 3Kempf T, Wollert KC. Growth differentiation factor-15: a new bi- omarker in cardiovascular disease[ Jl. Herz, 2009,34 (8) :5994- 5999.
  • 4Kempf T, Eden M, Strelau 3, et al. The :ransforming growth fac- tor-beta superfamily member growth-differentiation faetor-15 pro- teets the heart from isehemia/reperfusion injury [ J ]. Cire Res, 2006,98 ( 3 ) :351-360.
  • 5Xu J, Kimball TR, Lorenz JN, et al. GDFI5/MIC-1 functions as a proteetive and antihypertrophie faetor released from the myocardi- mn in association with SMAD protein activation [ J]. Cire Res, 2006,98 ( 3 ) : 342-350.
  • 6Kempf T, Widera C, Bavendiek U, et al. Growth-differentiation faetor-15 promotes anti-inflammatory effects and enhances survival after experimental myocardial infarction [ J ]. Circulation, 2007, 116: 11165.
  • 7Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth- differentiation factor-15 in patients with non-ST-elevation aeute coronary syndrome [ J ]. Circulation, 2007,115 ( 8 ) :962 -97 I.
  • 8Wollert KC, Kempf T, Lagerqvist B, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treat- ment strategy in non ST-elevation acute coronary syndrome [ J ]. Circulation, 2007,116 ( 14 ) : 1540-1548.
  • 9Kempf T, Sinning JM, Quint A, et al. Growth-differentiation fac- tor-15 for risk stratification in patients with stable and unstable cor- onary heart disease: results from the AtheroGene study[ J 1- Circ Cardiovasc Genet, 2009,2 (3) :286-292.
  • 10Khan SQ, Ng K, Dhillon O, et al. Growth differentiation factor-15 asa prognostic marker in patients with acute myocardial infarction [ J ]. Eur Heart J, 2009,30(9) :I057-I065.

同被引文献78

  • 1杨璇,李玉,李长江,冯磊.GDF-15与心肌梗死后心室重塑指标的相关性[J].中国老年学杂志,2015,35(1):59-60. 被引量:12
  • 2李江津,田晓沂,马树人.介入封堵术对先天性心脏病患者血浆脑钠素水平的影响[J].现代医学,2007,35(1):11-13. 被引量:2
  • 3王卫平,毛萌,李廷玉,等.儿科学[M].8版.北京:人民卫生出版社,2014:269-287.
  • 4Balode I, Minte I, Latkovskis G, et al. Insufficient comrol of heart rate in stable coronary artery disease patients in Latvia[ J ]. Medici- ha(Kaunas) ,2014,50 (5) :295-302.
  • 5Elbarouni B, Cantor WJ, Ducas J, et al. Efficacy of an Early Inva- sive Strategy After Fibrinolysis in ST-Elevation Myocardial Infarc- tion Relative to the Extent of Coronary Artery Disease[ J]. Can J Cardiol,2014,30(12) : 1555-1561.
  • 6Perrone-Filardi P, Savarese G, Scarano M, et al. Prognostic impact of metabolic syndrome in patients with chronic heart failure : Data from GISSI-HF trial [ J]. Int J Cardio1,2014,23,178C :85-90.
  • 7Berthiaume JM,Young ME, Chert X, et al. Normalizing the meta- bolic phenotype after myocardial infarction : impact of subchronic high fat feeding[ J]. J Mol Cell Cardiol,2012,53 (1) :125-133.
  • 8Lygate CA, Bohl S,ten Hove M, et al. Moderate elevation of intra- cellular crcatine by targeting the creatine transporter protects mice from acute myocardial infarction[ J ]. Cardiovasc Res ,2012,1,96 (3) :466-475.
  • 9Xu Y, Jiang L, Huang Y, et al. Solid-state characterization and transformation of various creatine phosphate sodium hydrates [ J ]. J Pharm Sei ,2014,103 ( 11 ) :3688-3695.
  • 10无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3684

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部